GSK shareholders to vote on Novartis megadeal in December

Glaxo shareholders will soon have the chance to weigh in on an asset swap between GlaxoSmithKline ($GSK) and Novartis ($NVS) worth more than $20 billion. The British pharma giant has asked its investors to vote at a Dec. 18 meeting on the proposed deal, which will send GSK's oncology drugs to Switzerland and most of Novartis' flu business to Glaxo, as well as establish a consumer healthcare JV. "This is the most significant transaction for the company since the creation of GlaxoSmithKline in 2000," GSK chairman Christopher Gent wrote in a shareholder letter seen by ReutersNews | More

Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.